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Abstract
Background: Melanoma is an aggressive skin cancer and a predominant cause of skin cancer-related deaths. A
previous study has demonstrated the ability of butein to inhibit tumor proliferation and invasion. However, the
anti-metastatic mechanisms and in vivo effects of butein have not been fully elucidated.
Methods: MTT cell viability assays were used to evaluate the antitumor effects of butein in vitro. Cytotoxic
effects of butein were measured by lactate dehydrogenase assay. Anti-migratory effects of butein were
evaluated by two-dimensional scratch and transwell migration assays. Signaling transduction and VEGF-releasing assays
were measured by Western blotting and ELISA. We also conducted an experimental analysis of the metastatic potential
of tumor cells injected into the tail vein of C57BL/6 mice.
Results: We first demonstrated the effect of butein on cell viability at non-cytotoxic concentrations (1, 3, and 10 μM).
In vitro, butein was found to inhibit the migration of B16F10 cells in a concentration-dependent manner using
transwell and scratch assays. Butein had a dose-dependent effect on focal adhesion kinase, Akt, and ERK
phosphorylation in B16F10 cells. Butein efficiently inhibited the mTOR/p70S6K translational inhibition machinery and
decreased the production of VEGF in B16F10 cells. Furthermore, the in vivo antitumor effects of butein were
demonstrated using a pulmonary metastasis model.
Conclusion: The results of the present study indicate the potential utility of butein in the treatment of melanoma.
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Background
The incidence of melanoma of the skin has rapidly
increased in recent years and is currently the most
common fatal form of skin cancer [1]. New Zealand has
the highest incidence of invasive melanoma worldwide
with an age-standardized rate of 40.2/100,000 [2]. Asian
populations, including China, India, Japan, and Singapore,
are reported to have relatively lower incidence rates
(approximately 1/100,000). Despite being a relatively rare
cancer, melanoma is associated with substantial morbidity
and mortality. This notorious aggressiveness of melanoma
is associated with its metastatic propensity, which can
occur even from shallow primary tumors [3]. According
to the clinical evidence, the survival rate in patients with
multiple site of metastasis disease is less than 5 % [4].
Despite significant progress in understanding the biology
of melanoma, new targets and immune-modulatory ther-
apies (such as vermurafenib and ipilimumab) have dem-
onstrated efficacy in improving the overall survival in
melanoma patients [5, 6]. However, the benefit of these
therapies is variable, and tumor metastasis still occurs in
majority of the melanoma patients.
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Surgery is the most important treatment for malignant
melanoma. However, late stage and metastatic melan-
oma is known to confer a very poor prognosis, with no
standard of care currently established. Drug therapies
for melanoma, including chemotherapy and targeted
therapy, are currently under development. The patho-
genesis of melanoma is complex and involves a number
of signaling pathways related to tumor cell growth and
metastasis [7]. Up-regulation of the mitogen activated
protein kinase (MAPK) signaling pathway is common in
many human cancers, including melanoma [8]. The
phosphatidylinositol 3-kinase (PI3K)/Akt signaling path-
way represents another key mediator of these processes.
PI3K can activate Akt and subsequently phosphorylate
several target proteins, including mammalian target of
rapamycin (mTOR). Following mTOR activation, cell
growth promotion and cell cycle progression may occur
because of mTOR downstream p70S6 kinase (p70S6K)
and eukaryotic initiation factor (eIF) 4E-binding protein
1 (4E-BP1) phosphorylation [9, 10]. The MAPK and
PI3K/Akt/mTOR signaling pathways are frequently acti-
vated and dysregulated in melanoma, and both represent
promising targets for melanoma treatment. Agents that
target the MAPK signaling pathway (AS/RAF/MEK/
ERK), such as vemurafenib (a BRAF inhibitor) and tra-
metinib (a MEK1/2 inhibitor), have increased survival in
patients with metastatic melanoma [11]. Inhibition of
the Akt/mTOR signaling pathway has also been shown
to abolish invasion and metastasis of highly-metastatic
melanoma cells [12]. MAPK and Akt/mTOR signaling
pathway inhibitors may represent promising targets for
the inhibition of melanoma cell invasion and metastasis.
Butein (3,4,2′,4′ -tetrahydroxychalcone) is a flavonoid
and chalcone derivative [13]. Flavonoids are phenolic
agents used in traditional Chinese and Tibetan herbal
medicines, which can be extracted from numerous plant
tissues, including the stem bark of cashews (Semecarpus
anacardium), the heartwood of Dalbergia odorifera, and
Caragana jubata and Rhus verniciflua stokes. Butein has
been found to have anti-oxidant, anti-inflammatory, and
anti-restenosis activities, which may be beneficial in dis-
ease treatment [14–16]. Recent studies have reported
that butein exhibits anti-angiogenesis, anti-proliferation,
and apoptotic effects against numerous cancer cell lines
[17–19]. In our previous study, we demonstrated that
butein significantly inhibited invasion of SK-Hep-1 cells,
a hepatoma cell line, via Akt/mTOR/p70S6K blockade
[20]. However, the effects of butein on tumor metastasis
are yet to be determined. Thus, we hypothesized that
butein has a similar inhibitory effect on Akt/mTOR/
p70S6K signaling pathway and the proliferation and me-
tastasis of melanoma cells. In the present study, we
aimed to elucidate the mechanisms underlying the anti-
metastatic effect of butein. We found that butein
diminished the PI3K/Akt/mTOR signaling pathway in
the mouse melanoma cell line, B16F10. In addition,
butein demonstrated potent anti-metastatic effects in a
model of lung metastasis.
Methods
Materials
2',3,4,4'-Tetrahydroxychalcone (butein) was purchased from
Extrasynthese Corporation (Genay, France). Dulbecco's
Modified Eagle Medium (DMEM), fetal bovine serum
(FBS), Antibiotic-Antimycotic and trypsin-EDTA were
purchased from Gibco (Grand Island, NY). Toluidine
blue O, RNase A and 3-[4,5-dimethylthiahiazo-2-y1]-
2,4-diphenytetrazolium bromide (MTT) were purchased
from Sigma Chemical Corporation (St Louis, MO, U.S.A.).
Lactate dehydrogenase (LDH) assay reagents were
purchased from Promega Corporation (Madison, WI).
Antibodies for phospho-Akt (Ser473), phospho-mTOR
(Ser2448) were purchased from Epitomics (Burlin-
game, CA). Antibodies for phospho-ERK1/2 (Thr202/
Tyr204), phospho-p70S6K (Thr389) and α-tubulin
were purchased from Cell Signaling Technologies
(Boston, MA).
Cell culture
Mouse melanoma cells (B16F10) were obtained from
the American Type Culture Collection. B16F10 cells
were cultured at 37 °C in HEPES-buffered Dulbecco’s
modified Eagle’s medium (DMEM), containing 10 % fetal
bovine serum (Gibco) supplemented with NaHCO3, glu-
tamax I (Gibco), 100 IU/mL penicillin G (sodium salt),
100 μg/mL streptomycin and 0.25 μg/mL amphotericin B
(antibiotic-antimitotic solution, Gibco).
Cell viability assay
B16F10 cells were sub-cultured onto 24-well plates and
starved with serum-free DMEM for 48 hours. Then,
melanoma cells were grown in DMEM, included 10 %
FBS in absence or presence of various concentrations of
butein (1, 3, 10 μM) for 48 hours. Cells were incubated
with MTT (0.5 mg/mL) for 4 hours. Formazan crystal
(purple) was lysed by dimethyl sulfoxide (DMSO) and
absorbance was measured at 550 nm with ELISA-reader
(Thermo, U.S.A.).
Lactate Dehydrogenase Assay
B16F10 cells were seeded onto 48-well plates in a
density of 2 × 104 cells/well and starvation for
48 hours with serum-free DMEM and incubated with
or without vehicle and indicated concentrations of
butein (1, 3 and 10 μM) in DMEM with 10 % FBS.
The percentage of LDH release was calculated from
the ratio of LDH activity in the medium to LDH ac-
tivity in the cell lysate.
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Migration assay
Migration assay of B16F10 cells was measured by
Coaster Transwells (polycarbonate filter, 8 μm pore size)
which were coated with 0.2 % gelatin. B16F10 cells
(5x104cell/well) were treated with vehicle or various
concentrations of butein (1, 3, 10 μM), and then cells
were seeded into the upper chamber. The bottom cham-
ber was added DMEM medium supplemented with 10 %
FBS. After incubation at 37 °C for 16 hr, all non-migrant
cells were removed from the upper face of the Transwell
membrane with a cotton swab, and the B16F10 cells that
had transmigrated through the micropore and that were
still bound to the membrane were fixed with 4 % paraf-
ormadehyde in PBS solution and stained with 0.5 %
toluidine blue in 4 % paraformadehyde. Migration was
quantified by counting the number of stained cells on
the membrane under a light microscope (Nikon, Japan)
at a magnification of 200× in 3 random fields, and then
photographed. All determinations were obtained by rep-
lication in at least three independent experiments.
Two-dimensional Migration Scratch Assay
Sub-cultured B16F10 cells were seeded into 6-well
plates. B16F10 cells were starved with serum-free
DMEM for 48 hours. Part of the dish was denuded by
scratching along a straight line with a 200 μl pipet tip
and incubated with or without vehicle and indicated
concentrations of butein (1, 3 and 10 μM) in DMEM
with 10 % FBS. After 16 hours of incubation at 37 °C,
images of the wounded area were captured immediately
by microscope (Nikon, Japan).
Western blotting
After cells pretreated with or without various concentra-
tions of butein (1, 3, 10 μM) and vehicle in serum-free
DMEM for 2 hours, cells were harvested and lysed in a
lysis buffer containing 15 mM Tris–HCl, 50 mM NaCl,
5 mM EGTA (ethyleneglycoltetraacetic acid), 1 % Triton
X-100, 1 % sodium deoxycholate, 0.1 % sodium dodecyl
sulfate (SDS), 1 mM NaF, 1 mM phenylmethylsulfonyl
fluoride (PMSF), 1 mM Na3VO4, 10 μg/mL aprotinin,
and 10 μg/mL leupeptin, pH 7.4. The protein samples
separated on 10 % SDS-PAGE were then transferred to
PVDF membranes by electro-blotting. The membranes
were blocked with 0.25 % (wt/vol) gelatin at room
temperature 1 hour. Afterward, immune-detection for
phosphorylated (activated) FAK, Akt, ERK, mTor,
p70S6K, eIF4E and α-tubulin were accomplished with
antibody in 0.25 % (wt/vol) gelatin. Blots were washed
for at least 30 mins in wash buffer (Tris/phosphate/sa-
line/Tween). After incubation with each antibody, the
immunoreactive band was detected by an Enhanced
Chemiluminiscence (ECL) Western blotting detection
system.
ELISA
B16F10 cells (105cells/well in 96well) were treated with
various concentrations of Butein or vehicle for 24 hr,
and then the supernatant was collected to examine the
amount of vascular endothelial growth factor (VEGF)
protein. VEGF mouse ELISA Kit (Novex®, Invitrogen)
was used according to the manufacturer’s instructions.
Animals
8-10 weeks-old male C57BL/6 mice were used in all
studies. All the experimental protocols regarding animal
study have been approved by the Institutional Animal
Care and Use Committee at College of Medicine, Tzu-Chi
University.
Experimental metastasis analysis
Metastasis analysis was performed as previously described
[21]. Briefly, B16F10 cells (2 × 106 cells) were slowly
injected into the lateral tail vein of C57BL/6 mouse to ini-
tiate tumor metastasis. Butein (1、3、10 mg/kg) was in-
traperitoneally administered to mice every day from
3 days before tumor cell injection to 21 days after tumor
cell injection (the day sacrified).
Statistical analysis
All values are presented as mean ± SEM. Differences be-
tween groups were assessed by one-way ANOVA and
Newman–Keuls multiple comparison test where appro-
priate. P values less than 0.05 (P < 0.05) were considered
to be significantly different.
Results
Effects of butein on the inhibition of B16F10 melanoma
proliferation
The structure of butein is shown in Fig. 1a. The effects
of butein on melanoma cell proliferation were deter-
mined by MTT assay. As shown in Fig. 1b, butein
inhibited B16F10 proliferation in a concentration-
dependent manner (IC50 = 9.53 μM). To confirm that
the anti-proliferative effect of butein was not because
of cytotoxicity, an LDH assay was also performed.
Our data indicates that butein does not have cyto-
toxic effects on B16F10 cells at a concentration of
10 μM (Fig. 1c).
Butein inhibits serum-stimulated cell motility
Migration is a major step in melanoma metastasis.
The pre-treatment addition of various concentrations
of butein (1, 3, and 10 μM) to the upper wells of transwell
chamber significantly inhibited B16F10s migration in re-
sponse to 10 % FBS (Fig. 2a). Furthermore, we produced
scrape wounds on B16F10 monolayers to observe the con-
tinuous movement of B16F10 cells in closing the gap that
was denuded. After 16 h of continuous treatment, butein
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(1, 3, and 10 μM) inhibited the serum-stimulated cell mo-
tility of melanoma cells (Fig. 3a). Migration responses of
melanoma cells in both modified Boyden chamber assays
and scrape models were significantly reduced in a
concentration-dependent manner.
Butein inhibits the ERK, focal adhesion kinase (FAK), and
PI3K/Akt/mTOR/p70S6K signaling pathways in melanoma
cells
The MAPK and PI3K/Akt/mTOR signaling pathways
are well-known important signaling pathways for melan-
oma growth and metastasis. Follow-up experiments were
designed to determine the effect of butein on signaling-
related protein phosphorylation in B16F10 cells. Butein
dramatically inhibited Akt and ERK1/2 phosphorylation
in a concentration-dependent manner in B16F10 cells.
mTOR, an important downstream effector of the PI3K/
Akt signaling pathway, is known to regulate translational-
related processes via stimulation of p70S6K and 4EBP1
phosphorylation. Thus, we evaluated the effects of butein
in the modulation of these signaling pathways. As shown
in Fig. 4a, serum (10 % FBS) induced a significant increase
in mTOR, p70S6K, 4E-BP1, and eIF4E phosphorylation.
In response to the serum, mTOR phosphorylation and
major downstream targets, including p70S6K, 4EBP, and
eIF4E, were significantly attenuated by butein treatment
in a concentration-dependent manner. The FAK-mediated
signaling cascade has also been shown to be involved in
melanoma migration and mitogenic responses [22]. Ac-
cordingly, we further assessed the effect of butein on FAK
phosphorylation. We observed that the levels of serum-
induced FAK phosphorylation were also inhibited by
butein. These results indicate that butein may inhibit
B16F10 growth and migration through the inhibition of
cellular signaling pathways.
Butein inhibits VEGF release
The expression and production of VEGF is regulated
by downstream transcript factors of the PI3K/Akt/
mTOR signaling pathway. Therefore, we examined the
effect of butein on VEGF release in B16F10 cells.
After 24-h treatment with various concentrations of
butein, supernatants were collected for analysis. VEGF
release was found to be suppressed by butein in a
concentration-dependent manner in B16F10 cells
(Fig. 5).
Butein inhibits in vivo pulmonary metastasis in
B16F10 cells
As the migration activity of B16F10 cells is associated
with tumor metastasis, we investigated the in vivo effect
of butein in a murine pulmonary metastasis model. Sin-
gle intravenous bolus injections of 2 × 106 B16F10 cells
were used to induce lung metastases. Butein (1, 3, or
10 mg/kg) was intraperitoneally administered to mice
from 3 days before tumor cell injection. Twenty-one
days later, the mice were euthanized, and their lungs
were removed. Mice treated with butein were found to
have a significant dose-dependent reduction in lung me-
tastases (Fig. 6a). The quantitative of lung metastasis
Fig. 1 The structure of butein and its effect on melanoma cells
viability and cytotoxicity. The structure of butein is shown in a.
B16F10 cells were seeded onto plates for 24 hr and starved for
another 24 hr with serum-free DMEM. b Quiescent cells were
cultivated with DMEM containing 10 % FBS in the absence or
presence of various concentrations of butein. After 48 h, cell viability
was detected by the MTT assay. c Cytotoxicity was detected by
manufacture’s protocol and finally recorded absorbance at 490 nm.
Control was taken as basal condition of LDH release. The results are
presented as percentages of inhibition (mean ± SEM, n = 4). All
P values were obtained from comparisons between control and
indicated concentration-treated cells. **, P < 0.01; ***, P < 0.001
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colony was shown in Fig. 6b. Butein significantly attenu-
ated pulmonary metastasis of B16F10 cells in vivo.
Discussion
Metastasis is a deadly stage in cancer progression and
the also is an important prerequisite for cancer me-
tastasis [23, 24]. There remains a lack of promising
therapeutic agents for the prevention of melanoma in-
vasion and metastasis. The results of the present
study demonstrated that a naturally occurring chalcone
derivative, butein, significantly inhibited melanoma prolif-
eration and migration in a concentration-dependent man-
ner (1, 3, and 10 μM) without significant cytotoxicity
(Fig. 1b, c). We previously reported that butein has
Fig. 2 Effect of butein on serum-stimulated B16F10 cell migration. a B16F10 cells (2 × 104) cultured in serum-free DMEM were pretreated with or
without butein for 30 minutes, and placed in the upper chamber of a Transwell containing with 0.2 % gelatin-coated filter membrane. DMEM
with 10 % FBS was added to the lower chamber. After removal of non-migrated cells and fixation, cells that migrated to the underside filter
membrane were stained and quantified by phase-contrast light microscope under a high-power field (HPF; magnification, 100×). Three fields per
filter were counted at 100× magnification. The quantitative of migratory cell was shown in b. Data are expressed as mean ± S.E.M. of five
independent experiments. *p < 0.05; **p < 0.01 compare with the control (Veh) group
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anti-metastatic activity by reducing MMP-9/uPA pro-
teolytic and Akt/mTOR/p70S6K translational activity
[20]. In the present study, butein treatment for 16 h
was found to inhibit cell migration at concentrations
ranging from 1 to 10 μM. Under similar conditions,
butein was found to induce substantial amounts of
cell death at a concentration of 10 μM only. These
data indicate that the migration inhibitory effect of
butein is not because of cytotoxicity. To the best of
our knowledge the present study is the first to
Fig. 3 Effect of butein on serum-stimulated B16F10 cell motility. a B16F10 cells (5 × 104) were seeded onto 6-well plates for 24 hr and starved for
another 24 hr with serum-free DMEM. Cells were subjected to injury by scratching with a plastic pipette tip (200 μl). The cells were then treated
for 24 hours with or without serum or butein. The quantitative of migratory cell was shown in b. Data are presented as percentages of control
(mean ± S.E.M., n = 3). **, P < 0.01 and ***,P < 0.001 versus control group
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provide evidence of the inhibitory effects of butein on
melanoma metastasis, without showing a significant
effect on cell proliferation. We demonstrated that
butein exhibited anti-metastatic activity at low con-
centrations (1 μM) without inducing significant cell
death in B16F10 cells. Notably, we also found that
butein significantly attenuated pulmonary metastasis
of B16F10 cells in vivo (Fig. 6). We also summarize
the contents and major findings in Fig. 7.
Dysregulation of the PI3K/Akt/mTOR signaling path-
way has been observed in various human cancers. As
the PI3K/Akt/mTOR signaling pathway regulates vari-
ous important cellular processes, it has become an
most important therapeutic targets for anti-cancer drug
development [9, 10, 25]. The mTOR signaling pathway
is a major chemotherapy target for the treatment of
cancers, including melanoma [11]. We found that
mTOR phosphorylation, its upstream kinases, PI3K,
Akt, and the downstream effector, p70S6K, in B16F10
cells (Fig. 4) were all effectively inhibited by butein.
The mTOR signaling pathway is also regulated by
PI3K/Akt-independent signaling pathways, such as
ERK, p38 MAPK, and AMPK [26]. FAK has been
shown to be important for melanoma cell proliferation,
adhesion, and invasion in vitro and in vivo [27]. FAK
inactivation reportedly results in decreased ERK phos-
phorylation and VEGF expression [22]. These studies
have demonstrated that FAK plays a critical role in mel-
anoma metastasis and may represent an anti-metastatic
target for melanoma treatment. As butein also signifi-
cantly inhibited the FAK and ERK signaling pathways,
the anti-cancer effect of butein may also be dependent
on the inhibition of the FAK and ERK signaling
pathways.
Activation of mTOR via the PI3K/Akt signaling
pathway is associated with increased translation of
hypoxia-inducible factor (HIF)-1α, which drives the
expression of angiogenic growth factors [28]. As
butein was found to inhibit mTOR activation, we
hypothesize that butein may suppress VEGF gene ex-
pression in B16F10 cells. Previous studies have re-
ported that aggressive melanoma cell lines express
higher levels of VEGF and that melanoma patients
with higher VEGF concentrations have a higher rate
of relapse [29, 30]. Inhibition of tumor growth has
been achieved in different melanoma xenograft
models through the use of a number of anti-VEGF
strategies [31]. In the present study, VEGF production
was decreased in B16F10 cells after 24-h treatment with
butein in a concentration-dependent manner (Fig. 5).
VEGF production has also been reported to be associated
with activation of downstream signaling pathways and
phenotypic changes, such as increased cell migration and
invasion [32]. Furthermore, VEGF expression has been
reported to have a correlation with apoptosis, and VEGF
reduces cell death through an autocrine mechanism
[33, 34]. The inhibitory effect of butein on VEGF ex-
pression may induce apoptosis of B16F10 cells in
addition to reducing tumor metastasis.
Fig. 4 Effect of butein on PI3K/Akt/mTOR, ERK and FAK pathways.
a B16F10 cells were incubated in the absence or presence of butein
(1- to 10 μM) for 12 hrs. Then, the cells were harvested and lysed for
the detection of the PI3K/Akt/mTOR, ERK and FAK pathways
activation by Western blot. The quantitative densitometry of the
relative level of protein phosphorylation (phosphortlation protein/
total protein) was performed with Image-Pro Plus and was shown in
b. Data are expressed as mean ± S.E.M. of five independent ex-
periments. The protein phosphorylation in all treatment cells
were significant lower than control (Veh) group (***p < 0.001 as
compare with control (Veh) group)
Fig. 5 Effects of butein on VEGF production in melanoma cells, B16F10.
VEGF protein expression was evaluated by ELISA in conditioned medium
of B16F10 in the presence or absence of butein at the indicated
concentrations. Data are represented as mean ± SEM (n = 6). *P < 0.05
and **P < 0.01 indicates significant differences from the vehicle control
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Surgery remains the major treatment for malignant
melanoma. However, the prognosis of melanoma re-
mains poor because of the invasiveness and metastasis
of the tumors [35]. Therefore, more efficacious treat-
ments for melanoma metastasis are required. Butein re-
duced the number of lung metastasis foci in a dose-
dependent manner in an in vivo pulmonary metastasis
model, indicating the anti-metastatic and antitumor ac-
tivities of butein towards melanoma (Fig. 6).
There are still some limitations in this study. Accord-
ing to the Flaherty et al. study, approximately 50 % of
melanomas harbor activating BRAF mutations [36].
Human melanomas display abnormal activation of the
MAPK cascade due to these mutations and may exhibit
sensitivity to MEK inhibition. Although the mouse
melanoma cell, B16F10, were without mutations in the
BRAF and NRAS genes, the MAPK cascade and PI3K/
Akt signaling pathway are still the major mediators for
Fig. 6 Effects of butein on experimental lung metastasis. a B16F10 cells (2x106) were injected into the lateral tail vein of C57BL/6 mouse. Twenty
days later, the lungs were removed, and surface-visible tumors were counted in the absence and presence of butein treatment. The melanoma
metastasis area of lung surface was black and background is dark red. White area was quantified using ImageJ software. The quantitative of lung
metastasis colony was shown in b. Corresponding bar graph expressed as percentage of vehicle (n = 8)
Fig. 7 Schematic presentation of butein-mediated signaling transduction modulation
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melanoma metastasis. So far, the best characterized of
metastasis models is the B16 melanoma model. B16F10
cells had an effective metastasis rate of 5 × 10-5 per cell
per generation [37]. Beside human melanoma cell trans-
planted null mice, this metastasis model in conjunction
with in vitro modeling and manipulation of tumor cells
have enable investigators to development of agents that
can be used to prevent or treat overt metastatic disease.
Conclusion
We demonstrated that butein inhibits tumor growth in
vitro by inhibiting the ERK and PI3K/Akt/mTOR
signaling pathways. VEGF production was found to be
decreased following butein treatment. More importantly,
butein exhibited anti-tumor activity by in vivo pulmonary
metastasis model. Collectively, the results of the present
study indicate that butein has potential anti-cancer prop-
erties for the treatment of melanoma. However, clinical
trials are required to fully validate the potential of butein
in clinical applications.
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